All In Biotech

Drug Trial Radar · NCT00911287

Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain

An Open-Label Effectiveness and Safety Study of Oxymorphone Extended Release in Opioid-Naive Patients With Chronic Pain.

Last checked: Nov 20, 2026Latest source record: Feb 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Jun 2003

Primary completion

Jan 2004

Study completion Mar 2004

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if oxymorphone ER is effective and safe in treating chronic pain in opioid-naive patients.

Conditions

  • Pain
  • Chronic Disease

Interventions

  • Oxymorphone extended releaseDrug

    Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tolerability.Time frame: Entire study duration, including follow-up period.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.